Maxim Group reaffirmed their hold rating on shares of Virpax Pharmaceuticals (NASDAQ:VRPX – Free Report) in a research report report published on Wednesday, Benzinga reports.
Virpax Pharmaceuticals Price Performance
NASDAQ:VRPX opened at $0.48 on Wednesday. The business’s fifty day moving average price is $0.82 and its 200 day moving average price is $1.49. Virpax Pharmaceuticals has a 1-year low of $0.46 and a 1-year high of $8.48.
Virpax Pharmaceuticals (NASDAQ:VRPX – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($1.75) earnings per share (EPS) for the quarter.
Virpax Pharmaceuticals Company Profile
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Featured Articles
- Five stocks we like better than Virpax Pharmaceuticals
- Upcoming IPO Stock Lockup Period, Explained
- The Future of Medical Devices: Two Strong Buys You Can’t Miss
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Momentum Trades for October With Ample Upside Ahead
- How to Evaluate a Stock Before Buying
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
